Halozyme Therapeutics, Inc. $HALO Shares Purchased by HB Wealth Management LLC

HB Wealth Management LLC increased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 281.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,202 shares of the biopharmaceutical company’s stock after buying an additional 10,483 shares during the period. HB Wealth Management LLC’s holdings in Halozyme Therapeutics were worth $1,112,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AlphaGrep UK Ltd purchased a new position in Halozyme Therapeutics in the second quarter valued at $340,000. BAM Wealth Management LLC boosted its stake in shares of Halozyme Therapeutics by 37.7% during the 2nd quarter. BAM Wealth Management LLC now owns 6,175 shares of the biopharmaceutical company’s stock worth $483,000 after acquiring an additional 1,691 shares in the last quarter. denkapparat Operations GmbH acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $390,000. AXQ Capital LP grew its position in shares of Halozyme Therapeutics by 111.8% during the 2nd quarter. AXQ Capital LP now owns 30,831 shares of the biopharmaceutical company’s stock valued at $2,413,000 after acquiring an additional 16,277 shares during the period. Finally, Orion Capital Management LLC increased its stake in shares of Halozyme Therapeutics by 14.7% in the 2nd quarter. Orion Capital Management LLC now owns 4,300 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 550 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on HALO. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. HC Wainwright restated a “buy” rating and issued a $115.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. TD Cowen increased their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $91.20.

Insider Activity at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at $79,987,320.40. The trade was a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 32,478 shares of company stock valued at $3,076,604. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Trading Down 0.4%

HALO stock opened at $107.00 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $111.15. The business’s 50-day moving average is $93.18 and its 200 day moving average is $76.75. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market cap of $12.14 billion, a price-to-earnings ratio of 31.94, a PEG ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.98 EPS for the current fiscal year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.